For the year ending 2025-12-31, NTLA made $67,671K in revenue. -$412,267K in net income. Net profit margin of -609.22%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 67,671 | 57,877 | ||
| Research and development | 388,861 | 466,311 | ||
| General and administrative | 119,800 | 125,829 | ||
| Total operating expenses | 508,661 | 592,140 | ||
| Operating loss | -440,990 | -534,263 | ||
| Interest income | 29,195 | 47,807 | ||
| Change in fair value of investments, net | -899 | -32,565 | ||
| Loss from equity method investment | 0 | - | ||
| Change in fair value of contingent consideration | 0 | - | ||
| Total other income, net | 28,296 | 15,242 | ||
| Net loss | -412,694 | -519,021 | ||
| Unrealized gain on marketable securities | 427 | 731 | ||
| Other comprehensive gain from equity method investment | 0 | - | ||
| Comprehensive loss | -412,267 | -518,290 | ||
| Basic EPS | -3.81 | -5.25 | ||
| Diluted EPS | -3.81 | -5.25 | ||
| Basic Average Shares | 108,376,000 | 98,849,000 | ||
| Diluted Average Shares | 108,376,000 | 98,849,000 | ||
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)